DelveInsight’s ‘Chemotherapy-induced Diarrhea Pipeline Insights‘ report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.
The Chemotherapy-induced Diarrhea Pipeline report provides a comprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.
Some of the key takeaways from the Chemotherapy-induced Diarrhea Pipeline report:
Request for Sample report to discover more about the therapies set to grab maximum patient pool @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights
Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.
Chemotherapy-induced Diarrhea Pipeline Drugs Immunostimulants
Drug
Company
Phase
MoA
RoA
FW-420
AzuRx BioPharma
Unknown
MTOR protein inhibitors
Oral/rectal
Mytesi
Napo Pharmaceuticals
Phase III
Chloride channel antagonists
Oral
OQL051
OnQuality Pharmaceuticals
Discovery
NA
DP 1038
Dauntless Pharmaceuticals
Phase II
Growth hormone-releasing hormone inhibitors;
Somatostatin receptor agonists
Intranasal
Chemotherapy-induced Diarrhea Therapeutic Assessment
The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
Scope of the Report Coverage: Global Key Players: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others. Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others.
Reach out @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights
Table of Contents
1
Report Introduction
2
Chemotherapy-induced Diarrhea Disease Overview
3
Chemotherapy-induced Diarrhea Pipeline Outlook
4
Comparative Analysis
5
Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage
6
Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage
7
Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis
8
Inactive Chemotherapy-induced Diarrhea Pipeline Products
9
Appendix
10
Report Methodology
11
Consulting Services
12
Disclaimer
13
About DelveInsight
Visit to know more of what’s covered @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/chemotherapy-induced-diarrhea-pipeline-insights